Keywords

ADHD, attention-deficit hyperactivity disorder, chronic obstructive pulmonary disease, COPD, diabetes mellitus, FDA drug approvals, hepatitis C, HIV, new drugs, plaque psoriasis

Authors

1. Meadowcraft, Lindsy PharmD, BCACP, CDE
2. Mospan, Geoffrey PharmD, BCPS
3. Morrisette, Taylor
4. Smart, Katie
5. Janis, Melissa

Abstract

Abstract: In 2016, the FDA approved several new drugs for use in primary care. These drugs include amphetamine extended-release orally disintegrating tablets (Adzenys XR-ODT), elbasvir and grazoprevir (Zepatier), emtricitabine and tenofovir alafenamide (Descovy), glycopyrrolate and formoterol (Bevespi Aerosphere), insulin degludec injection (Tresiba), and ixekizumab (Taltz).